Galectin Therapeutics Inc. (GALT) Announces Quarterly Earnings Results
Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01, Bloomberg Earnings reports. During the same period last year, the business earned ($0.20) EPS.
Shares of Galectin Therapeutics (NASDAQ GALT) opened at 1.83 on Tuesday. Galectin Therapeutics has a 52 week low of $0.49 and a 52 week high of $3.68. The stock has a 50 day moving average price of $2.20 and a 200-day moving average price of $2.24. The firm’s market capitalization is $63.45 million.
Hedge funds have recently added to or reduced their stakes in the stock. Buckingham Asset Management LLC bought a new stake in Galectin Therapeutics during the first quarter worth $115,000. Cutter & CO Brokerage Inc. increased its stake in Galectin Therapeutics by 57.2% in the first quarter. Cutter & CO Brokerage Inc. now owns 56,600 shares of the company’s stock worth $130,000 after buying an additional 20,600 shares during the last quarter. Northern Trust Corp increased its stake in Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares during the last quarter. KCG Holdings Inc. increased its stake in Galectin Therapeutics by 1.9% in the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after buying an additional 1,592 shares during the last quarter. Finally, Virtu KCG Holdings LLC increased its stake in Galectin Therapeutics by 24.4% in the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after buying an additional 21,008 shares during the last quarter. Hedge funds and other institutional investors own 11.00% of the company’s stock.
Several research analysts have issued reports on the company. ValuEngine lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $2.25.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.